{"id":"NCT02580591","sponsor":"Boehringer Ingelheim","briefTitle":"Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)","officialTitle":"A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of Once Daily, Oral Doses of Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-3)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-22","primaryCompletion":"2017-09-12","completion":"2017-09-20","firstPosted":"2015-10-20","resultsPosted":"2018-11-02","lastUpdate":"2018-11-02"},"enrollment":977,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 1"],"interventions":[{"type":"DRUG","name":"Empagliflozin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Empagliflozin low dose","type":"EXPERIMENTAL"},{"label":"Empagliflozin high dose","type":"EXPERIMENTAL"},{"label":"Empagliflozin medium dose","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study will investigate the efficacy, safety, tolerability and Pharmacokinetic(PK) of 3 doses of empagliflozin compared with placebo over 26 weeks in 960 patients with type 1 diabetes mellitus as adjunctive therapy to insulin","primaryOutcome":{"measure":"Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Full Analysis Set (FAS) (Observed Cases [OC])","timeFrame":"Baseline to week 26","effectByArm":[{"arm":"Placebo Matching Empagliflozin","deltaMin":0.2,"sd":0.05},{"arm":"Empagliflozin 2.5 Milligram (mg)","deltaMin":-0.09,"sd":0.05},{"arm":"Empagliflozin 10 mg","deltaMin":-0.25,"sd":0.05},{"arm":"Empagliflozin 25 mg","deltaMin":-0.33,"sd":0.05}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":19},"locations":{"siteCount":189,"countries":["United States","Australia","Canada","Czechia","Finland","France","Germany","Greece","Hungary","Ireland","Italy","Latvia","Mexico","Netherlands","New Zealand","Norway","Poland","Portugal","Romania","Russia","South Africa","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["37616393","30287422"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":241},"commonTop":["Hypoglycaemia","Nasopharyngitis","Urinary tract infection","Blood ketone body increased"]}}